RxDoctor Payments Data

Melissa Klein, DO

Neurology · Lexington, KYNPI 1821093675

Payments from drug & device makers

$6,950in general payments, 2019–2025

Across 456 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$566
  • Amgen$526
  • Novartis$443
  • Lilly USA, LLC$426
  • Teva Pharmaceuticals USA, Inc.$425
  • plus $3K from 39 others

What the payments were for

  • Speaking & faculty fees$1041%
  • Food & beverage$6,82898%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,950 in reported general payments places this provider in the 60th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$70,067
Medicare patients
220
Services billed
4,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Plegridy PenPeginterferon Beta-1a12$96,040
Dimethyl Fumarate21$60,337
UbrelvyUbrogepant29$38,726
QuliptaAtogepant12$24,685
NeuproRotigotine13$24,377
RexultiBrexpiprazole16$22,012
Emgality PenGalcanezumab-Gnlm15$15,215
Memantine Hcl ErMemantine Hcl50$10,181
Entacapone25$5,135
Rivastigmine19$3,181
Memantine Hcl120$3,106
Pyridostigmine Bromide26$2,944
FingolimodFingolimod Hcl12$2,778
Carbidopa-LevodopaCarbidopa/Levodopa88$2,484
Sumatriptan Succinate26$1,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,409$63,41141 claims
UCB, Inc.Neupro$566$24,37713 claims
Otsuka America Pharmaceutical, Inc.Rexulti$18$22,01216 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$114$2,94426 claims
Upsher-smith Laboratories LLCTopiramate$15$64648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 210 neurology providers in Kentucky.

Other neurology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →